JP7824664B2 - Ｋｃｎｔ１阻害剤及び使用方法 - Google Patents

Ｋｃｎｔ１阻害剤及び使用方法

Info

Publication number
JP7824664B2
JP7824664B2 JP2023500279A JP2023500279A JP7824664B2 JP 7824664 B2 JP7824664 B2 JP 7824664B2 JP 2023500279 A JP2023500279 A JP 2023500279A JP 2023500279 A JP2023500279 A JP 2023500279A JP 7824664 B2 JP7824664 B2 JP 7824664B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
group
alkoxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023500279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532985A (ja
JP2023532985A5 (cg-RX-API-DMAC10.html
Inventor
アンドリュー マーク グリフィン
ボテージャ ガブリエル マルティネス
Original Assignee
プラクシス プレシジョン メディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラクシス プレシジョン メディシンズ， インコーポレイテッド filed Critical プラクシス プレシジョン メディシンズ， インコーポレイテッド
Publication of JP2023532985A publication Critical patent/JP2023532985A/ja
Publication of JP2023532985A5 publication Critical patent/JP2023532985A5/ja
Application granted granted Critical
Publication of JP7824664B2 publication Critical patent/JP7824664B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023500279A 2020-07-06 2021-07-06 Ｋｃｎｔ１阻害剤及び使用方法 Active JP7824664B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063048335P 2020-07-06 2020-07-06
US63/048,335 2020-07-06
PCT/US2021/040486 WO2022010880A1 (en) 2020-07-06 2021-07-06 Kcnt1 inhibitors and methods of use

Publications (3)

Publication Number Publication Date
JP2023532985A JP2023532985A (ja) 2023-08-01
JP2023532985A5 JP2023532985A5 (cg-RX-API-DMAC10.html) 2024-07-11
JP7824664B2 true JP7824664B2 (ja) 2026-03-05

Family

ID=79552679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500279A Active JP7824664B2 (ja) 2020-07-06 2021-07-06 Ｋｃｎｔ１阻害剤及び使用方法

Country Status (10)

Country Link
US (1) US20230219921A1 (cg-RX-API-DMAC10.html)
EP (1) EP4175624A4 (cg-RX-API-DMAC10.html)
JP (1) JP7824664B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230035608A (cg-RX-API-DMAC10.html)
CN (1) CN116075297A (cg-RX-API-DMAC10.html)
AU (1) AU2021305058A1 (cg-RX-API-DMAC10.html)
CA (1) CA3188825A1 (cg-RX-API-DMAC10.html)
IL (1) IL299700B2 (cg-RX-API-DMAC10.html)
MX (1) MX2023000360A (cg-RX-API-DMAC10.html)
WO (1) WO2022010880A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4446314A3 (en) * 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
CN120817941A (zh) * 2019-05-03 2025-10-21 普拉克西斯精密药物股份有限公司 Kcnt1抑制剂和使用方法
EP4110317B1 (en) 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
JP2025514140A (ja) * 2022-04-25 2025-05-02 プラクシス プレシジョン メディシンズ， インコーポレイテッド ピラゾールコアを含むｋｃｎｔ１阻害剤及び使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127547D0 (en) * 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
US20050026968A1 (en) * 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
CN101711245B (zh) * 2007-07-19 2015-03-25 H.隆德贝克有限公司 5元杂环酰胺及相关的化合物
CN113710318A (zh) * 2019-04-26 2021-11-26 H.隆德贝克有限公司 作为Kv3钾通道激活剂的芳基磺酰基噻吩甲酰胺和芳基磺酰基呋喃甲酰胺
EP4446314A3 (en) * 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI

Also Published As

Publication number Publication date
KR20230035608A (ko) 2023-03-14
IL299700A (en) 2023-03-01
CN116075297A (zh) 2023-05-05
EP4175624A4 (en) 2024-08-07
JP2023532985A (ja) 2023-08-01
IL299700B2 (en) 2026-06-01
EP4175624A1 (en) 2023-05-10
AU2021305058A1 (en) 2023-02-09
MX2023000360A (es) 2023-02-23
CA3188825A1 (en) 2022-01-13
WO2022010880A1 (en) 2022-01-13
IL299700B1 (en) 2026-02-01
US20230219921A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
JP7667573B2 (ja) Ｋｃｎｔ１阻害剤および使用する方法
JP7838820B2 (ja) Ｋｃｎｔ１阻害剤及び使用方法
JP7671990B2 (ja) Ｋｃｎｔ１阻害剤および使用する方法
JP2023532985A (ja) Ｋｃｎｔ１阻害剤及び使用方法
JP7699836B2 (ja) Ｋｃｎｔ１阻害剤、および使用方法
WO2022140547A2 (en) Kcnt1 inhibitors and methods of use
EP4329735B1 (en) Kcnt1 inhibitors and methods of use
JP2025514140A (ja) ピラゾールコアを含むｋｃｎｔ１阻害剤及び使用方法
WO2023122152A1 (en) Kcnt1 inhibitors and methods of use
WO2024123717A1 (en) Kcnt1 inhibitors comprising a phenyl, pyridine, or pyrimidine core and methods of use
WO2022231872A1 (en) Kcnt1 inhibitors and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7824664

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150